Overview
LifeArc provides intellectual property management, technology development, early-stage drug discovery, antibody humanization, and diagnostics development services to academic, biotech, and pharmaceutical organizations. It offers funding, partnerships, and commercialization support to translate research into therapies, with successes including pembrolizumab and lecanemab. Profits are reinvested into further medical research focused on rare diseases and global health challenges.
Frequently asked questions
- What services does LifeArc offer for drug discovery and development?
- LifeArc offers early-stage drug discovery, antibody humanization, technology development, and commercialization services, including IP identification, protection, and licensing for academic, biotech, and pharma partners.
- Does LifeArc support diagnostics development?
- Yes, LifeArc provides full diagnostics development from assay design and verification to clinical validation, focusing on early detection, disease progression, companion diagnostics, and novel biomarkers aligned with specific health challenges.
- What are LifeArc's therapeutic focus areas and funding options?
- LifeArc targets rare diseases, global health challenges like TB, motor neuron disease, and childhood cancers, offering funding through open calls, investments via LifeArc Ventures, and partnerships for gene therapy and translational research.